Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lebrikizumab in Atopic Dermatitis Previously Treated With Dupilumab
NCT05369403Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2022
- Primary completion
- Jan 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of lebrikizumab in atopic dermatitis (AD), sponsored by Eli Lilly and Company. Started Dec 2022; status: completed.
02
Drugs
lebrikizumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05369403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05369403.